Literature DB >> 17653103

Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus.

Jin Cheng1, Harald Sauthoff, YaoQi Huang, David I Kutler, Sofia Bajwa, William N Rom, John G Hay.   

Abstract

The success of replicating adenoviruses for cancer therapy is limited by inefficient virus delivery and poor distribution within the tumor mass. Stromal matrix within the tumor may hinder the free cell-to-cell spread of the virus. In this study, in vitro cell culture experiments showed that collagen I blocked the passage of an adenoviral vector through a membrane. On the basis of reports of the effective collagen I-degrading activity of matrix metalloproteinase-8 (MMP-8), we constructed an adenovirus to express the MMP-8 transgene (AdMMP8). A549 cells infected in vitro with AdMMP8 did not show altered growth but were able to modify a fibrillar collagen substrate to allow viral diffusion. Further, AdMMP8 did not affect replication of the wild-type virus (Adwt300). Established human A549 lung cancer and BxPC-3 pancreatic cancer xenograft tumors that were injected with Adwt300 together with the non-replicating AdMMP8 virus showed significantly reduced growth compared with control tumors. Histochemical analysis showed reduced amounts of collagen within necrotic areas of MMP-8-injected tumors compared with controls. These results demonstrate that intra-tumoral expression of MMP-8 is a possible strategy for improving viral spread and improving the oncolytic activity of replicating adenovirus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653103     DOI: 10.1038/sj.mt.6300264

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  30 in total

1.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

Review 2.  Impact of tumor microenvironment on oncolytic viral therapy.

Authors:  Jeffrey Wojton; Balveen Kaur
Journal:  Cytokine Growth Factor Rev       Date:  2010 Apr-Jun       Impact factor: 7.638

Review 3.  Site-specific gene therapy for cardiovascular disease.

Authors:  Ilia Fishbein; Michael Chorny; Robert J Levy
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

4.  Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography.

Authors:  Alan R Penheiter; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  J Gene Med       Date:  2012 Sep-Oct       Impact factor: 4.565

5.  Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection.

Authors:  C-S Hong; W Fellows; A Niranjan; S Alber; S Watkins; J B Cohen; J C Glorioso; P Grandi
Journal:  Gene Ther       Date:  2010-05-13       Impact factor: 5.250

6.  Nanoparticles functionalized with collagenase exhibit improved tumor accumulation in a murine xenograft model.

Authors:  Surya Murty; Taylor Gilliland; Peter Qiao; Tate Tabtieng; Elizabeth Higbee; Ajlan Al Zaki; Ellen Puré; Andrew Tsourkas
Journal:  Part Part Syst Charact       Date:  2014-12       Impact factor: 3.310

Review 7.  Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery.

Authors:  Aaron Dolor; Francis C Szoka
Journal:  Mol Pharm       Date:  2018-05-16       Impact factor: 4.939

Review 8.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

9.  Toward a stem cell gene therapy for breast cancer.

Authors:  ZongYi Li; Ying Liu; Sebastian Tuve; Ye Xun; Xiaolong Fan; Liang Min; Qinghua Feng; Nancy Kiviat; Hans-Peter Kiem; Mary Leonora Disis; André Lieber
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

10.  Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Authors:  Timothy Kottke; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Dragan Jevremovic; Glen N Barber; Geoff Hall; John Chester; Peter Selby; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-04-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.